Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002340 · ClinicalTrials.gov registry record · Phase 3
A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
- 615
- Enrollment target
NCT00002340 is a Phase 3 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 615 participants.
The verdict
NCT00002340, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 615 participants
- Enrollment target
Study Summary
To assess whether high dose or low dose atovaquone suspension is more effective than aerosolized pentamidine as prophylaxis against Pneumocystis carinii pneumonia (PCP) in high-risk HIV-infected patients. To compare the safety of chronic administration of the three regimens in patients with advanced HIV disease. To determine the relationship between steady state atovaquone plasma concentrations and prophylactic efficacy against PCP.
Interventions
- DRUG Atovaquone
- DRUG Pentamidine isethionate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 615 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002340
The ClinicalTrials.gov registry entry for NCT00002340 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 615 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Atovaquone is the first listed.
NCT00002340 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002340 about?
NCT00002340 is a clinical study titled "A Comparison of Atovaquone and Pentamidine in the Prevention of Pneumocystis Carinii Pneumonia in HIV-Infected Patients Who Cannot Take TMP/SMX". To assess whether high dose or low dose atovaquone suspension is more effective than aerosolized pentamidine as prophylaxis against Pneumocystis carinii pneumonia (PCP) in high-risk HIV-infected patients. To compare the safety of chronic administration of the three regimens in patients with advanced...
What is the current status of trial NCT00002340?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 615 participants.
What interventions are being tested in trial NCT00002340?
The interventions under investigation include: Atovaquone (DRUG), Pentamidine isethionate (DRUG).
Who is sponsoring clinical trial NCT00002340?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.